Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients

Dobes,Petr; Podhorec,Jan; Coufal,Oldrich; Jureckova,Andrea; Petrakova,Katarina; Vojtesek,Borivoj; Hrstka,Roman

doi:10.3892/or.2014.3346

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients

Authors:
- Petr Dobes
- Jan Podhorec
- Oldrich Coufal
- Andrea Jureckova
- Katarina Petrakova
- Borivoj Vojtesek
- Roman Hrstka
View Affiliations

Affiliations: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic, Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic
Published online on: July 21, 2014 https://doi.org/10.3892/or.2014.3346
Pages: 1695-1702

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High rates of mutation in the TP53 tumor suppressor gene have been found in many human cancers, including breast tumors, making p53 one of the most studied proteins in oncology. However, the prognostic and predictive value of alterations in this gene remains ambiguous. To analyze the clinical value of somatic TP53 mutations, we collected clinical and molecular data on 210 women with primary breast cancer. We found significant associations of p53 mutations with tumor grade, metastasis, molecular subtype, Her2 status and inverse correlations with estrogen and progesterone receptor status. Cox proportional hazard analysis confirmed a strong prognostic value of p53 mutation for overall survival rate and highlighted significant interactions with lymph node involvement and tumor size. In relation to treatment options, TP53 mutations were associated with poor response to anthracyclines and radiotherapy. Categorization of TP53 mutations according to their type and location revealed that patients with nonsense mutation have the poorest prognosis in comparison with wild-type cases and other types of mutations in this gene. Classification of TP53 mutations with respect to the degree of disturbance of protein structure showed association of disruptive mutations with poorer patients' outcome in contrast to wild-type and non-disruptive mutations. In conclusion, the present study confirms p53 as a potential predictive and prognostic factor in oncology practice and highlights the growing evidence that distinct types of mutations have different clinical impacts.

View Figures

View References

1	Dušek L, Mužík J, Gelnarová E, Fínek J, Vyzula R and Abrahámová J: Cancer incidence and mortality in the Czech Republic. Klin Onkol. 23:311–324. 2010.
2	Cancer Research UK. www.cancerresearchuk.orghttps://www.cancerresearchuk.org. Accessed March, 2013
3	Kastan MB, Canman CE and Leonard CJ: P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 14:3–15. 1995. View Article : Google Scholar
4	Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304–6311. 1991.PubMed/NCBI
5	Soussi T and Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 1:233–239. 2001.
6	Greenblatt M, Bennett W, Hollstein M and Harris C: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–4878. 1994.
7	Caron de Fromentel C and Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer. 4:1–15. 1992.PubMed/NCBI
8	Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
9	Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:346–355. 1994. View Article : Google Scholar : PubMed/NCBI
10	Bertheau P, Espié M, Turpin E, et al: TP53 status and response to chemotherapy in breast cancer. Pathobiology. 75:132–139. 2008. View Article : Google Scholar
11	Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 329:1318–1327. 1993. View Article : Google Scholar : PubMed/NCBI
12	Olivier M, Langerød A, Carrieri P, et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 12:1157–1167. 2006. View Article : Google Scholar : PubMed/NCBI
13	Poeta ML, Manola J, Goldwasser MA, et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007. View Article : Google Scholar
14	Hrstka R, Beranek M, Klocova K, Nenutil R and Vojtesek B: Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep. 22:1205–1211. 2009.PubMed/NCBI
15	Elston C and Ellis I: Assessment of histological grade. The Breast. 13. Churchill Livingstone; Edinburgh, New York: pp. 356–384. 1998
16	Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012.PubMed/NCBI
17	Geisler S, Lønning PE, Aas T, et al: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505–2512. 2001.
18	Chrisanthar R, Knappskog S, Løkkevik E, et al: CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 3:e30622008. View Article : Google Scholar : PubMed/NCBI
19	Wahl AF, Donaldson KL, Faircnild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 2:72–79. 1996. View Article : Google Scholar : PubMed/NCBI
20	Chrisanthar R, Knappskog S, Løkkevik E, et al: Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One. 6:e192492011.PubMed/NCBI
21	Bonnefoi H, Piccart M, Bogaerts J, et al: TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1–00): a randomised phase 3 trial. Lancet Oncol. 12:527–539. 2011. View Article : Google Scholar
22	Geisler S, Børresen-Dale AL, Johnsen H, et al: TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res. 9:5582–5588. 2003.
23	Powell B, Soong R, Iacopetta B, Seshadri R and Smith DR: Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res. 6:443–451. 2000.PubMed/NCBI
24	Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, et al: Prognostic and predictive value of TP53 mutations in nodepositive breast cancer patients treated with anthracycline-or anthracycline/taxane-based adjuvant therapy: results from the BIG 02–98 phase III trial. Breast Cancer Res. 14:R702012.
25	Lai H, Ma F, Trapido E, Meng L and Lai S: Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res Treat. 83:57–66. 2004. View Article : Google Scholar : PubMed/NCBI